Intravesical Ozone Therapy for Interstitial Cystitis/Bladder Pain Syndrome

Launched by MEDIPOL UNIVERSITY · Mar 3, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a treatment called intravesical ozone therapy for patients with interstitial cystitis (IC) or bladder pain syndrome. The goal is to see if this therapy can help relieve symptoms like pain and discomfort. In this trial, 60 participants will be divided into three groups: one will receive ozone therapy, another will get a placebo (a treatment that looks the same but has no active ingredients), and the third group will continue with standard care. The study will last for three weeks, and participants will be followed up six weeks after the treatment to assess how well the therapy worked.

To be eligible for the trial, participants must be between 18 and 65 years old and have a confirmed diagnosis of interstitial cystitis with symptoms lasting at least six months. They should also be willing to sign a consent form. However, people with active urinary tract infections, certain bladder conditions, or those who are pregnant or breastfeeding cannot join. This trial is not yet recruiting participants, but once it does, those who qualify will have the opportunity to contribute to research that could help improve treatment for bladder pain.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-65 years
• • Histopathologically or clinically confirmed IC (per AUA guidelines)
• • Symptoms for at least 6 months
• • Willing to provide informed consent
• Exclusion Criteria:
• • Active urinary tract infection
• • Bladder malignancy
• • Pregnancy or breastfeeding
• • Known ozone allergy
• • Intravesical therapy within 3 months
• • G6PD deficiency